Events

Rappel de ARCHITECT Free T4 Reagent. An in vitro diagnostic medical device (IVD)List Numbers: 7K65-29 (100 Test Kit), 7K65-34 (2000 Test Kit) and 7K65-39 (500 Test Kit)Multiple Lot Numbers (see attached)ARTG Number: 180112

Selon Department of Health, Therapeutic Goods Administration, ce/cet/cette rappel concerne un dispositif en/au/aux/à Australia qui a été fabriqué par Abbott Australasia Pty Ltd Diagnostic Division.

Qu'est-ce que c'est?

Une correction ou un retrait opéré par un fabricant afin de répondre à un problème causé par un dispositif médical. Les rappels surviennent lorsqu'un dispositif médical est défectueux, lorsqu'il pourrait poser un risque pour la santé, ou les deux à la fois.

En savoir plus sur les données ici
  • Type d'événement
    Recall
  • ID de l'événement
    RC-2017-RN-00562-1
  • Classe de risque de l'événement
    Class II
  • Date de mise en oeuvre de l'événement
    2017-05-02
  • Pays de l'événement
    Australia
  • Source de l'événement
    DHTGA
  • URL de la source de l'événement
    https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2017-RN-00562-1
  • Notes / Alertes
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notes supplémentaires dans les données
  • Cause
    Abbott diagnostics is providing information regarding a change of measuring interval for the architect free t4 assay list numbers 7k65-29, 7k65-34 and 7k65-39.The current measuring interval is 0.40 ng/dl (5.15 pmol/l) to 6.00 ng/dl (77.22 pmol/l).Recent data generated by abbott have determined that the measuring interval is 0.40 ng/dl (5.15 pmol/l) to 5.00 ng/dl (64.35 pmol/l). this new measuring range will be included in a future version of the instructions for use and the new ft4 assay file. there is no impact to patient results with values between 0.40 ng/dl (5.15 pmol/l) and 5.0 ng/dl (64.35 pmol/l). only the measuring interval between 5.00 – 6.00 ng/dl (64.35 – 77.22 pmol/l) is affected.
  • Action
    Abbott is advising users that patient sample results between 5.00 ng/dL (64.35 pmol/L) and 6.00 ng/dL (77.22pmol/L) should be reported as >5.00 ng/dL (64.35pmol/L). In addition, the customer letter should be reviewed with the laboratory’s management for potential impact specific to laboratory procedures such as internal ranges.

Device

ARCHITECT Free T4 Reagent. An in vitro diagnostic medical device (IVD)List Numbers: 7K65-29 (100 ...
  • Modèle / numéro de série
    ARCHITECT Free T4 Reagent. An in vitro diagnostic medical device (IVD)List Numbers: 7K65-29 (100 Test Kit), 7K65-34 (2000 Test Kit) and 7K65-39 (500 Test Kit)Multiple Lot Numbers (see attached)ARTG Number: 180112
  • Manufacturer
    Abbott Australasia Pty Ltd Diagnostic Division

Manufacturer

Abbott Australasia Pty Ltd Diagnostic Division
  • Société-mère du fabricant (2017)
    Abbott Laboratories
  • Commentaire du fabricant
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DHTGA